Last updated on February 2018

Study of NAC of GA Therapy for Patients With BRPC

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pancreatic Ductal Adenocarcinoma
  • Age: Between 20 - 79 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Histologically or cytologically diagnosed as pancreatic adenocarcinoma, and consistent with NCCN guideline (Version 2. 2016) borderline resectable-arterial, borderline resectable-venous
  2. Case with measurable lesion
  3. First line treatment
  4. PS (ECOG) 0-1
  5. >= 20 years old and <80 years old
  6. The following criteria must be satisfied in laboratory tests within 14 days of registration
    • WBC count<=12,000/mm3
    • Neutrophil count>=1,500/mm3
    • Hb >= 9.0g/dl
    • Plt >= 100,000/mm3
    • T.Bil <2.0mg/dl (<3=.0mg/dl in biliary drainage case)
    • Serum Cr<=upper limits of normal (ULN)
    • AST, ALT <= 2.5xULN
  7. Written informed consent to participate in this study

Exclusion Criteria:

  1. Severe drug hypersensitivity
  2. Multiple primary cancers within 5 years
  3. Severe infection
  4. With grade2 or more severe peripheral neuropathy
  5. Interstitial pneumonia or pulmonary fibrosis
  6. With uncontrollable pleural effusion or ascites
  7. With uncontrollable diabetes mellitus
  8. With uncontrollable heart failure, angina, hypertension, arrhythmia
  9. With severe neurological/psychological symptoms
  10. With watery diarrhea
  11. Pregnant or lactating women or women with unknown or suspected pregnancy
  12. Inappropriate patients for entry on this study in the judgement of the investigator
  13. Diagnosed as Resectable/Unresectable pancreatic carcinoma on NCCN guideline (Version 2.2016)

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.